147 related articles for article (PubMed ID: 32707342)
1. Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.
Trivedi PJ; Muir AJ; Levy C; Bowlus CL; Manns MP; Lu X; Crans G; Chung C; Subramanian GM; Myers RP; Goodman Z; Chalasani N; Vierling JM; Guha IN; Hirschfield GM
Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1248-1257. PubMed ID: 32707342
[TBL] [Abstract][Full Text] [Related]
2. Fluctuating biomarkers in primary sclerosing cholangitis: A longitudinal comparison of alkaline phosphatase, liver stiffness, and ELF.
Fossdal G; Mjelle AB; Wiencke K; Bjørk I; Gilja OH; Folseraas T; Karlsen TH; Rosenberg W; Giil LM; Vesterhus M
JHEP Rep; 2021 Oct; 3(5):100328. PubMed ID: 34485881
[TBL] [Abstract][Full Text] [Related]
3. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
4. Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease.
Muir AJ; Levy C; Janssen HLA; Montano-Loza AJ; Shiffman ML; Caldwell S; Luketic V; Ding D; Jia C; McColgan BJ; McHutchison JG; Mani Subramanian G; Myers RP; Manns M; Chapman R; Afdhal NH; Goodman Z; Eksteen B; Bowlus CL;
Hepatology; 2019 Feb; 69(2):684-698. PubMed ID: 30153359
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
Eaton JE; Nelson KM; Gossard AA; Carey EJ; Tabibian JH; Lindor KD; LaRusso NF
Scand J Gastroenterol; 2019 May; 54(5):633-639. PubMed ID: 31131678
[No Abstract] [Full Text] [Related]
6. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.
Trauner M; Gulamhusein A; Hameed B; Caldwell S; Shiffman ML; Landis C; Eksteen B; Agarwal K; Muir A; Rushbrook S; Lu X; Xu J; Chuang JC; Billin AN; Li G; Chung C; Subramanian GM; Myers RP; Bowlus CL; Kowdley KV
Hepatology; 2019 Sep; 70(3):788-801. PubMed ID: 30661255
[TBL] [Abstract][Full Text] [Related]
7. Enhanced liver fibrosis test predicts transplant-free survival in primary sclerosing cholangitis, a multi-centre study.
de Vries EMG; Färkkilä M; Milkiewicz P; Hov JR; Eksteen B; Thorburn D; Chazouillères O; Pares A; Nygård S; Gilja OH; Wunsch E; Invernizzi P; Carbone M; Bernuzzi F; Boberg KM; Røsjø H; Rosenberg W; Beuers UH; Ponsioen CY; Karlsen TH; Vesterhus M
Liver Int; 2017 Oct; 37(10):1554-1561. PubMed ID: 28267887
[TBL] [Abstract][Full Text] [Related]
8. Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis.
Rupp C; Rössler A; Halibasic E; Sauer P; Weiss KH; Friedrich K; Wannhoff A; Stiehl A; Stremmel W; Trauner M; Gotthardt DN
Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1292-301. PubMed ID: 25316001
[TBL] [Abstract][Full Text] [Related]
9. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
Fickert P; Hirschfield GM; Denk G; Marschall HU; Altorjay I; Färkkilä M; Schramm C; Spengler U; Chapman R; Bergquist A; Schrumpf E; Nevens F; Trivedi P; Reiter FP; Tornai I; Halilbasic E; Greinwald R; Pröls M; Manns MP; Trauner M;
J Hepatol; 2017 Sep; 67(3):549-558. PubMed ID: 28529147
[TBL] [Abstract][Full Text] [Related]
10. Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.
Trauner M; Gindin Y; Jiang Z; Chung C; Subramanian GM; Myers RP; Gulamhusein A; Kowdley KV; Levy C; Goodman Z; Manns MP; Muir AJ; Bowlus CL
JHEP Rep; 2020 Feb; 2(1):100060. PubMed ID: 32039401
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
12. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study.
Hirschfield GM; Gershwin ME; Strauss R; Mayo MJ; Levy C; Zou B; Johanns J; Nnane IP; Dasgupta B; Li K; Selmi C; Marschall HU; Jones D; Lindor K;
Hepatology; 2016 Jul; 64(1):189-99. PubMed ID: 26597786
[TBL] [Abstract][Full Text] [Related]
13. Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value.
de Vries EM; Wang J; Leeflang MM; Boonstra K; Weersma RK; Beuers UH; Geskus RB; Ponsioen CY
Liver Int; 2016 Dec; 36(12):1867-1875. PubMed ID: 26945698
[TBL] [Abstract][Full Text] [Related]
14. Short-term prognostic factors for primary sclerosing cholangitis.
Watanabe T; Hirano K; Tada M; Isayama H; Mizuno S; Arizumi T; Toda N; Sugawara Y; Kokudo N; Koike K
J Hepatobiliary Pancreat Sci; 2015 Jun; 22(6):486-90. PubMed ID: 25826613
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of immune-modulating therapy for primary sclerosing cholangitis: A systematic review and meta-analysis.
Liu X; Wang H; Liu X; Bridle K; Crawford D; Liang X
Pharmacol Ther; 2022 Sep; 237():108163. PubMed ID: 35271884
[TBL] [Abstract][Full Text] [Related]
16. Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M; Bowlus CL; Gulamhusein A; Hameed B; Caldwell SH; Shiffman ML; Landis C; Muir AJ; Billin A; Xu J; Liu X; Lu X; Chung C; Myers RP; Kowdley KV
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1552-1560.e2. PubMed ID: 35934287
[TBL] [Abstract][Full Text] [Related]
17. Cholangiocarcinoma is associated with a raised enhanced liver fibrosis score independent of primary sclerosing cholangitis.
Saffioti F; Roccarina D; Vesterhus M; Hov JR; Rosenberg W; Pinzani M; Pereira SP; Boberg KM; Thorburn D
Eur J Clin Invest; 2019 May; 49(5):e13088. PubMed ID: 30762236
[TBL] [Abstract][Full Text] [Related]
18. Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis.
Vesterhus M; Hov JR; Holm A; Schrumpf E; Nygård S; Godang K; Andersen IM; Naess S; Thorburn D; Saffioti F; Vatn M; Gilja OH; Lund-Johansen F; Syversveen T; Brabrand K; Parés A; Ponsioen CY; Pinzani M; Färkkilä M; Moum B; Ueland T; Røsjø H; Rosenberg W; Boberg KM; Karlsen TH
Hepatology; 2015 Jul; 62(1):188-97. PubMed ID: 25833813
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
Eksteen B; Bowlus CL; Montano-Loza AJ; Lefebvre E; Fischer L; Vig P; Martins EB; Ahmad J; Yimam KK; Pockros PJ; Feld JJ; Minuk G; Levy C
Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
[TBL] [Abstract][Full Text] [Related]
20. An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort.
Bakhshi Z; Hilscher MB; Gores GJ; Harmsen WS; Viehman JK; LaRusso NF; Gossard AA; Lazaridis KN; Lindor KD; Eaton JE
J Gastroenterol; 2020 May; 55(5):523-532. PubMed ID: 31932891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
